Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Stockholm: Clusterin (or Beware the Evil Chaperone!)
22 July 2002. Stockholm. Injecting a fresh set of data into the debate about what is toxic and why-fibrillar amyloid or early, oligomeric forms of Aβ-scientists at the 8th International Conference on Alzheimer’s Disease and Related Disorders today presented their work on clusterin, an Aβ binding protein also called ApoJ. The study appears today in the Proceedings of the National Academy of Sciences.

Ron DeMattos, David Holtzman and colleagues of Washington University, St. Louis, with others at Eli Lilly and Co. and at University of Cincinnati College of Medicine, took earlier in vitro work on interactions between clusterin and Aβ in vivo by breeding PDAPP mice with a clusterin knockout strain.

They found that mice overproducing Aβ but lacking clusterin accumulated and deposited as much amyloid as did mice that had clusterin. However, the amyloid was different. The clusterin-free PDAPP mice had fewer fibrillar deposits and altered pools of soluble Aβ. At the same time, they showed markedly less neuritic dystrophy around the sites of amyloid deposition in their brains. This finding uncouples amyloid deposition from neurotoxicity and points a finger at an intriguing protein that modifies the formation of toxic amyloid species. ApoE and ApoJ/clusterin are the two most abundant apolipoproteins in the brain.

With clusterin, a larger proportion of Aβ converted to thioflavine-S positive fibrillar amyloid than without clusterin. How could it work? This remains unclear, but DeMattos et al. suggest that clusterin might promote the formation of toxic oligomeric forms of Aβ, as previous in vitro studies have suggested.

It is unclear how clusterin’s observed effect of changing soluble Aβ pools in vivo relates to its other observed effect of modifying fibrillization in a way that increases toxicity. An emerging literature is beginning to describe clusterin as a secreted chaperone, which can solubilize different proteins that have in common that they expose hydrophobic sites. Perhaps chaperone-like interactions between clusterin and Aβ change the equilibrium between soluble and deposited Aβ, the authors speculate. This could unmask epitopes that increase toxicity to neurites, either on soluble Aβ or on fibrillar amyloid.-Gabrielle Strobel

Reference:DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10843-10848.

 
Comments on News and Primary Papers
  Primary Papers: Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease.

Comment by:  Richard Mayeux, ARF Advisor
Submitted 13 August 2002  |  Permalink Posted 13 August 2002
  I recommend this paper
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad